Extended Data Fig. 7: Gremlin1 antibody treatment in mice does not cause major side effects in vivo.
(a) Binding specificity of anti-murine Gremlin1 antibody to Gremlin1 is validated by the enzyme-linked immunosorbent assay (n = 2 technical replicates, experiments have been repeated twice). Ab is anti-Gremlin1 in this figure. (b) Gremlin was mainly expressed by the tumorous epithelial cells in castrated Pbsn-Cre4; Ptenfl/fl; Trp53fl/fl PCa. Scale bars = 20μm. The immunostaining experiment was repeated at least twice. The representative images were presented. (c) Grem1 was most highly expressed in the prostate cancer tissue compared to other organs from Pbsn-Cre4; Ptenfl/fl; Trp53fl/fl mice (n = 3 mice). (d, e) Gremlin1 antibody treatment does not induce major side effects when administered systemically to mice (10 mg/kg three times a week). No obvious alterations are detected in peripheral blood cell counts (d, IgG: n = 5 mice; Ab: n = 7 mice) or major organs (e) in mice received the antibody treatment. Scale bars: left panel = 2 mm; right panel = 100 μm. Ab: anti-murine Gremlin1. (Two-tailed Student’ s t test was used for the statistical analysis. Data are presented as means ± s.e.m.).
